US-based medical device company Interventional Spine has secured US Food and Drug Administration (FDA) approval for its 80 lumbar lordotic opticage expandable intervertebral body fusion device.
The device adds to the company’s portfolio of opticage expandable interbody fusion devices and can be used with its PerX360 System.
The Lordotic 80 Opticage is a lumbar intervertebral body fusion device and is designed to be used with autogenous bone graft in patients afflicted with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1.
Lumbar Lordosis is a kind of DDD which causes the spine in the lower back to abnormally curve which, increasing stress on the lower spine resulting in pain for the patient.
The new Lordotic 80 Opticage can be used as an option by surgeons to correct pressure on the lower spine which relieves the pain caused by lordosis.
It provides the option to be implanted via posterior, transforaminal or lateral approach, additionally it offers optimum graft injection through its patented delivery system.
Interventional Spine CEO Joseph Darling said: "Based on existing market trends, Interventional Spine expect the new Lordotic Opticages to be a significant source of revenue for the company.
"More and more surgeons have been requesting a Lumbar Lordotic expandable cage from us.
"We are very excited with the latest addition of the Lordotic 80 Opticage, as it provides a pathway for Interventional Spine’s vision of becoming a leader in the expandable cage market, and addresses the needs of Surgeons and Patients world-wide."
Interventional Spine is currently exploring to evolve its line of lordotic expandable opticages in various sizes and configurations.
Image: A horse with pronounced lordosis. Photo: courtesy of I, Montanabw.
